Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

AIMS: Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce, Figueroa, Amparo L, Alexander, Veronica J, Tami, Joseph, Witztum, Joseph L, Geary, Richard S, O’Dea, Louis St L, Tsimikas, Sotirios, Gaudet, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986458/
https://www.ncbi.nlm.nih.gov/pubmed/35025993
http://dx.doi.org/10.1093/eurheartj/ehab820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986458/
https://www.ncbi.nlm.nih.gov/pubmed/35025993
http://dx.doi.org/10.1093/eurheartj/ehab820

Ejemplares similares